Cortisone in Ulcerative Colitis Preliminary Report on a Therapeutic Trial

Truelove, S. C.

doi:10.1159/000199983

Cited by 739 publications

(1,033 citation statements)

References 0 publications

Supporting

Mentioning

955

Contrasting

Unclassified

Order By: Relevance

“…Patients' disease activity was assessed by the Truelove and Witts activity score, 8 number of liquid stools per day and C-reactive protein. Signi®cance of improvement in disease activity and stool frequency was assessed using the Wilcoxon signed rank sum test.…”

Section: Methodsmentioning

confidence: 99%

Treatment of corticosteroid‐resistant ulcerative colitis with heparin —a report of 16 cases

Evans

Wong

Morris

et al. 1997

Aliment Pharmacol Ther

135

View full text Add to dashboard Cite

Background:Heparin, a group of sulphated glycosaminoglycans, in addition to its anticoagulant activity, has a wide range of potentially anti‐inflammatory effects. These include inhibition of neutrophil elastase and inactivation of chemokines. Previous reports of fortuitous improvement in ulcerative colitis patients treated with heparin for prophylaxis of venous thrombosis, prompted us to perform a pilot study in patients with corticosteroid‐resistant ulcerative colitis.Methods:Sixteen hospitalized patients in relapse from ulcerative colitis and unresponsive to high‐dose corticosteroid therapy were treated with intravenous standard heparin (subcutaneous in two patients), the dose was adjusted to provide standard anticoagulant activity. Five patients continued with subcutaneous injections on discharge, with a gradual reduction in the frequency of doses.Results:Within 1 week of starting heparin, 12/16 patients had shown a considerable reduction in stool frequency. After 2 weeks of heparin therapy median stool frequency had improved from 8.0/day (range 6.3–10.0) pre‐treatment to 3.5/day (2.5–5.25) (P=0.008), and by 4 weeks 12/16 achieved clinical remission. Four patients required elective colectomy. Three patients were treated with heparin on a second occasion during a relapse, two failed to respond and required subsequent colectomy. Nine remain well. No serious complications were seen due to the anticoagulant activity, apart from bruising at subcutaneous injection sites.Conclusion:The response to heparin in patients with ulcerative colitis resistant to standard therapy is encouraging and supports the previous uncontrolled evidence for a therapeutic effect. A controlled trial of heparin in ulcerative colitis is clearly indicated.

show abstract

Section: Methodsmentioning

confidence: 99%

Treatment of corticosteroid‐resistant ulcerative colitis with heparin —a report of 16 cases

Evans

Wong

Morris

et al. 1997

Aliment Pharmacol Ther

135

View full text Add to dashboard Cite

show abstract

“…Fifteen patients with mild/moderate ulcerative colitis de®ned by the Truelove and Witts criteria 9 were studied, including eight male patients and seven females with a mean age of 44 years, range 27±66. Eleven had leftsided disease and four extensive.…”

Section: Patients Studiedmentioning

confidence: 99%

Treatment of ulcerative colitis with an engineered human anti‐TNFα antibody CDP571

Evans

Clarke

Heath

et al. 1997

Aliment Pharmacol Ther

130

View full text Add to dashboard Cite

Background:Tumour Necrosis Factor‐alpha (TNFα) is a pro‐inflammatory cytokine whose expression is increased in the colonic mucosa of patients with active ulcerative colitis. TNFα antibodies have been shown to be beneficial in animal models of bowel inflammation and in Crohn's disease but have not previously been studied in ulcerative colitis.Methods:Patients with mild/moderate ulcerative colitis were treated openly with a single intravenous infusion of 5 mg/kg of an engineered human IgGγ4 antibody CDP571 and monitored for 8 weeks.Results:Fifteen patients entered the study, eight males and seven females, with a mean age of 44 years. Eleven had left‐sided disease, four extensive disease and six patients were steroid‐unresponsive. The treatment was well tolerated and plasma half‐life of CDP571 was ≈7 days. There was a significant reduction from 6.7 to 4.6 (P = 0.023) in the mean Powell–Tuck score by 1 week post‐infusion and a reduction to 5.5 was seen at 2 weeks (P = 0.218). Significant but modest reductions also occurred in erythrocyte sedimentation rate and serum C reactive protein in the first 2 weeks. Mean Interleukin‐6 plasma concentrations fell from 6.9 to 5.4 pg/mL by week 1, and to 6.1 pg/mL by week 2 (NS). Reductions in sigmoidoscopic score and number of liquid stools were noted but failed to reach statistical significance.Conclusion:A consistent improvement in disease activity was seen in the initial 2 weeks after infusion and the treatment was well tolerated. These promising results support the testing of CDP571 in a larger controlled trial.

show abstract

“…For determination of MRPs in serum 62 patients with UC fully characterized with regard to anatomical distribution of disease and investigated for laboratory parameters as well as single activity indices were included in the study. Activity of UC was determined according to Rachmilewitz [I61 and using the criteria of Truelove & Witts [17]. Patients were receiving the following medical treatments at the time of study: 28 patients were treated with steroids only, eight with steroids and 5-amino-salicylic acid or sulfasalazine and 10 with 5-amino-salicylic acid or sulfasalazine only.…”

Section: Pat Ien T Samples and Pat Ient Populat Ionmentioning

confidence: 99%

The myeloic related protein MRP8/14 (27E10 antigen)— usefulness as a potential marker for disease activity in ulcerative colitis and putative biological function

Lügering

Stoll

Schmid

et al. 1995

Eur J Clin Investigation

View full text Add to dashboard Cite

Abstract. MRP8, MRP14 and their heterodimer MRP8/14 (27E10 antigen) are myeloic related proteins which have been shown to have a major role in inflammatory and immunological responses. In the present study monospecific antibodies against MRPs were used to investigate immunohistochemically the distribution of these proteins in routinely processed bowel tissues from 23 patients with ulcerative colitis (UC). MRP8, MRP14 and their heterocomplex MRP8/l4 were demonstrated in the majority of granulocytes and macrophages in tissues of patients with active UC. Furthermore by employing the ELISA technique we measured MRP8/14 serum levels in 62 patients with UC and the results were compared with those for healthy controls. Disease activities were determined by established clinical activity indices. Serum MRP8/14 concentrations were significantly ( P < 0.0001) increased in patients with active ulcerative colitis. No enhancement of serum levels were found for MRP14 and MRP8 alone, respectively. The follow-up of individual patients with initially active disease showed a decrease of MRP8/14 serum levels in parallel with clinical improvement following the start of therapy. It is thus concluded that MRP8/14 accurately reflects the degree of disease activity in UC. Further, possible biological function of MRPs seems to be associated with the heterodimeric form (27E10 antigen) rather than with individual proteins. Our morphological results confirm the finding of enhanced MRP8/14 serum levels in patients with active UC.

show abstract

Cortisone in Ulcerative Colitis Preliminary Report on a Therapeutic Trial

Cited by 739 publications

References 0 publications

Treatment of corticosteroid‐resistant ulcerative colitis with heparin —a report of 16 cases

Treatment of corticosteroid‐resistant ulcerative colitis with heparin —a report of 16 cases

Treatment of ulcerative colitis with an engineered human anti‐TNFα antibody CDP571

The myeloic related protein MRP8/14 (27E10 antigen)— usefulness as a potential marker for disease activity in ulcerative colitis and putative biological function

Contact Info

Product

Resources

About